Vabysmo vs Vuity
A side-by-side look at two eye health medications advertised on TV. Informational only — not medical advice.
| US Vabysmo | US Vuity | |
|---|---|---|
| Generic name | faricimab | pilocarpine ophthalmic |
| Drug class | VEGF/Ang-2 Bispecific Inhibitor (Eye Injection) | Cholinergic Muscarinic Agonist (Eye Drop) |
| Treats | Wet macular degeneration, diabetic macular edema | Age-related blurry near vision (presbyopia) |
| Category | Eye Health | Eye Health |
| Manufacturer | Genentech (Roche) | AbbVie (Allergan) |
| Year approved | 2022 | 2021 |
| FDA warning | No boxed warning | No boxed warning |
| Est. TV ad spend | $85M | $70M |
| Common side effects | Eye inflammation, Floaters, Increased eye pressure, Blurred vision | Headache, Eye redness, Trouble with night vision, Eye pain |
Frequently asked questions
Is Vabysmo or Vuity better?
Neither is universally "better." Vabysmo (faricimab) and Vuity (pilocarpine ophthalmic) are both used for eye health, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Vabysmo and Vuity?
Vabysmo is a VEGF/Ang-2 Bispecific Inhibitor (Eye Injection) made by Genentech (Roche), while Vuity is a Cholinergic Muscarinic Agonist (Eye Drop) made by AbbVie (Allergan). See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Vabysmo has the larger estimated TV advertising budget of the two.